Hertz, D L <br/><br/>
CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Jun 2013 
 - 1472-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdt018  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Black or African American--genetics<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents, Phytogenic--therapeutic use<br/>Aryl Hydrocarbon Hydroxylases--genetics<br/>Breast Neoplasms--drug therapy<br/>Cohort Studies<br/>Cytochrome P-450 CYP2C8<br/>Female<br/>Genetic Variation--genetics<br/>Humans<br/>Middle Aged<br/>Paclitaxel--adverse effects<br/>Paraneoplastic Polyneuropathy--chemically induced<br/>Risk Factors<br/>Treatment Outcome<br/>White People--genetics<br/>Young Adult